MedTrace Logo

Breast MRI in Evaluation of Pathologic Response in Patients With Breast Cancer With Neoadjuvent Chemotherapy

NCT05301790 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2022-03-31

No results posted yet for this study

Summary

evaluation of pathological response in breast mass by use of breast MRI in patients receiving neoadjuvent chemotherapy via comparison with pathological results

Conditions

  • Role of MRI in Evaluation of Breast Cancer

Interventions

DEVICE

MRI

use of MRI modality of imaging in evaluation of pathologic response in patients with breast cancer

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • lamiaa mohamed refaat, assisstant professor · assiut university -south egypt cancer institute

  • omar mostafa, lecturer · assiut university-south egypt cancer institute

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2024-06-30
Completion
2024-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05301790 on ClinicalTrials.gov